Хайлтын үр дүнгүүд - Shebl, Amgad

  • 6-н 1 - 6 үр дүнгүүдийг харуулж байна
Үр дүнг сайжруулах
  1. 1
    Anti‐A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital‐based cohort study

    Anti‐A/B isoagglutinin reduction in an intravenous immunoglobulin product and risk of hemolytic anemia: a hospital‐based cohort study -н Wallenhorst, Christopher, Patel, Ami, Shebl, Amgad, Hubsch, Alphonse, Simon, Toby L., Martinez, Carlos

    Хэвлэсэн 2020
    Бүрэн текст авах Бүрэн текст авах Бүрэн текст авах
    текст
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    Impact of screening and exclusion of high anti‐A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital‐based cohort study in the US

    Impact of screening and exclusion of high anti‐A titer donors on the risk of hemolytic anemia with intravenous immunoglobulin treatment: A hospital‐based cohort study in the US -н Martinez, Carlos, Watson, Douglas J., Shebl, Amgad, Wallenhorst, Christopher, Hubsch, Alphonse, Simon, Toby L.

    Хэвлэсэн 2017
    Бүрэн текст авах Бүрэн текст авах Бүрэн текст авах
    текст
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis of spontaneous adverse event reports

    Isoagglutinin reduction in intravenous immunoglobulin (IgPro10, Privigen) by specific immunoaffinity chromatography reduces its reporting rates of hemolytic reactions: an analysis... -н Shebl, Amgad, Gabriel, Susie, Van Dinther, Kristy, Hubsch, Alphonse, Lawo, John‐Philip, Hoefferer, Liane, Welsh, Susan

    Хэвлэсэн 2020
    Бүрэн текст авах Бүрэн текст авах Бүрэн текст авах
    текст
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme

    Safety of biweekly α(1)-antitrypsin treatment in the RAPID programme -н Greulich, Timm, Chlumsky, Jan, Wencker, Marion, Vit, Oliver, Fries, Michael, Chung, Thomas, Shebl, Amgad, Vogelmeier, Claus, Chapman, Kenneth R., McElvaney, Noel G.

    Хэвлэсэн 2018
    Бүрэн текст авах Бүрэн текст авах Бүрэн текст авах
    текст
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study)

    Efficacy and safety of Privigen® in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA stu... -н Léger, Jean-Marc, De Bleecker, Jan L, Sommer, Claudia, Robberecht, Wim, Saarela, Mika, Kamienowski, Jerzy, Stelmasiak, Zbigniew, Mielke, Orell, Tackenberg, Björn, Shebl, Amgad, Bauhofer, Artur, Zenker, Othmar, Merkies, Ingemar S J

    Хэвлэсэн 2013
    Бүрэн текст авах Бүрэн текст авах Бүрэн текст авах
    текст
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneuropathy And Treatment with Hizentra study

    Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre‐randomization phase of the Polyneur... -н Mielke, Orell, Bril, Vera, Cornblath, David R., Lawo, John‐Philip, van Geloven, Nan, Hartung, Hans‐Peter, Lewis, Richard A., Merkies, Ingemar S.J., Sobue, Gen, Durn, Billie, Shebl, Amgad, van Schaik, Ivo N.

    Хэвлэсэн 2019
    Бүрэн текст авах Бүрэн текст авах Бүрэн текст авах
    текст
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: